WHITE PLAINS, N.Y., Sept. 5, 2012 /PRNewswire/ -- Parthenon Associates, LLC ("Parthenon" www.parthenonassociates.com), a Financial Consulting firm that provides research and strategic advisory services to Life Sciences, Biotechnology, and Development-Stage Technology companies, has released its report on Targeted Payload Cancer Therapeutics (TPCTs). The report examines the promise of TPCTs, drugs that combine precision cancer-targeting agents with toxins or radioisotopes, to create powerful and safe treatments for many forms of cancer with a $15 billion market potential. An in-depth analysis of the dynamic cancer market, cancer treatment, TPCT development, TPCT economic and reimbursement issues, as well as an examination of companies developing these novel drugs are included.
About the authors
The 100+ page report was compiled over several months by a team with extensive and varied experience in healthcare. Key members are:
About our services
Parthenon Associates provides research and strategic advisory services to companies in the Life Sciences, Biotechnology, and Development-Stage Technology industries. Parthenon's Corporate Services include advising companies on product development acquisitions and product licensing, investor relations, and capital markets issues.
Robert LeBoyer, Principal. T: (914) 594-4931. firstname.lastname@example.org.
|SOURCE Parthenon Associates, LLC|
Copyright©2012 PR Newswire.
All rights reserved